NCCM
ROSG

Nine Chapters Capital Management’s Rosetta Genomics Ltd. ROSG Stock Holding History

Nine Chapters Capital Management’s Portfolio ROSG Stock Details ROSG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,142
Closed -$44K – 1037
2013
Q3 		$44K Buy
+1,142
New +$46.3K 0.01% 717

Other funds holding ROSG

OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
WA
WFG Advisors Dallas, Texas $442M AUM 12.46% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Nine Chapters Capital Management's ROSG Position: Q4 2013 in Review

Nine Chapters Capital Management sold out of Rosetta Genomics Ltd. (ROSG) in Q4 2013, closing a stake of 1,142 shares — an estimated $44K sold.

Nine Chapters Capital Management first reported a position in ROSG in Q3 2013 and held it in 1 quarter. The position peaked at $44K in Q3 2013. 11 funds tracked by Wall St. Rank hold ROSG as of Q4 2013.

  • Nine Chapters Capital Management reported no remaining Rosetta Genomics Ltd. position as of Q4 2013 after selling out during the quarter.
  • Nine Chapters Capital Management sold 1,142 Rosetta Genomics Ltd. shares in Q4 2013, an estimated $44K.
  • Nine Chapters Capital Management first reported a position in Rosetta Genomics Ltd. in Q3 2013 and held it in 1 quarter.
  • Nine Chapters Capital Management's Rosetta Genomics Ltd. position peaked at $44K in Q3 2013.
  • 11 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q4 2013.

Based on Nine Chapters Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.